Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1625 1634 1691
This examiner grants 78% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18291630 | PHOSPHATE PRODRUGS OF CANNABINOIDS | Non-Final OA | Emory University |
| 18694597 | INSECT, ACARINA AND NEMATODE PEST CONTROL | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18674715 | SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 | Non-Final OA | Massachusetts Institute of Technology |
| 18722233 | COMBINATION OF AN A2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | Non-Final OA | BAYER AKTIENGESELLSCHAFT |
| 18830080 | Complexes and Ligands | Non-Final OA | The General Hospital Corporation |
| 18663765 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INDUCING ANTIMICROBIAL INTRACELLULAR ACTIVITY AND FOR PREVENTING AND TREATING MICROBIAL INFECTIONS | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 18566008 | COMPOSITIONS OF CLOFAZIMINE AND AMIKACIN FOR PULMONARY ADMINISTRATION IN THE TREATMENT OF RESPIRATORY DISEASES | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18885056 | FORMS OF PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES, ITS FORMULATION AND ITS PROCESS OF MAKING | Non-Final OA | Hoffmann-La Roche Inc. |
| 18980424 | BICYCLOOCTANE KRAS INHIBITORS | Non-Final OA | Incyte Corporation |
| 18675743 | PYRAZOLOQUINOLINE KRAS INHIBITORS | Non-Final OA | INCYTE CORPORATION |
| 17762325 | TREATMENT AND PREVENTION OF AGING RELATED-DISEASE AND/OR AGING BY THE INHIBITION OF SPHINGOLIPIDS | Non-Final OA | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) |
| 18419894 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | Final Rejection | Celgene Corporation |
| 18702178 | DETOXIFYING AGENT, DETOXIFYING AGENT KIT, AND NOVEL INCLUSION COMPLEX | Non-Final OA | THE DOSHISHA |
| 18694487 | STABLE FORMULATIONS OF BUPRENORPHINE | Final Rejection | ELANCO US INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy